After his sinister role on The Handmaid’s Tale, Josh Charles is switching gears to Fox’s upcoming small town show Best ...

This was the stock's second consecutive day of gains.

The stock's rise snapped a four-day losing streak.

On Monday, Chase Infiniti proved her breakout star status with a Golden Globe nomination for her role in One Battle After ...

Kite, a Gilead Sciences company, recently reported new analysis showing that its CAR T therapy Yescarta delivers consistent ...

The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...

A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another ...

Arcus Biosciences (RCUS) stock falls as the company and partner Gilead (GILD) halt a Phase 3 cancer trial evaluating its anti ...

Arcus Biosciences said on Friday it would stop a late-stage study testing its experimental cancer drug combination in ...

Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...

Arcus Biosciences and Gilead Sciences are discontinuing a Phase 3 trial of an experimental cancer treatment after an interim review showed the therapy was unlikely to help patients live longer.

Gilead and Arcellx reported promising data for their CAR-T therapy anito-cel at the annual American Society of Hematology ...